Get the Daily Brief
Latest Biotech News
CRISPR pushes beyond therapeutics: glowing spider silk and nitrogen‑fixing wheat
Researchers used CRISPR to engineer nontraditional organisms for applied outcomes: a team edited spiders to produce red‑glowing silk, the first demonstration of fluorescent silk spun in vivo, and...
Biogen backs Versant’s Dayra: $50M deal launches oral macrocycle push
Biogen signed an early collaboration with newly launched Dayra Therapeutics—backed by Versant Ventures—paying $50 million up front to discover and optimize oral macrocyclic peptide candidates for...
NervGen reports durable SCI gains: NVG‑291 shows extended functional benefit
NervGen released expanded CONNECT phase Ib/IIa data showing that NVG‑291, a 35‑amino‑acid peptide, produced durable functional improvements in people with chronic spinal cord injury that persisted...
AI flags liver risk: Cellarity’s model predicts DILI with high accuracy
Cellarity published a toxicogenomics framework and an AI model (ToxPredictor) built on DILImap, a large transcriptomics resource, to predict dose‑related drug‑induced liver injury (DILI). The...
Tempus buys OneOme pharmacogenetics assets after abrupt shutdown
Tempus confirmed acquisition of the pharmacogenetics (PGx) assets of OneOme after the Minneapolis‑based company ceased operations. The deal transfers OneOme’s RightMed test technology,...
Cheap, fast RNA‑seq shakes up cores: Plasmidsaurus launches $50 assay
Plasmidsaurus launched a shallow‑depth RNA‑seq transcriptome service priced at $50 per academic sample with a turnaround under three days, offering 10 million deduplicated 3' end reads for gene...
Abbott doubles down on oncology diagnostics: $23B Exact Sciences buy
Abbott announced a definitive agreement to acquire Exact Sciences for $23 billion, a transaction expected to close in the second quarter of 2026. Abbott CEO Robert Ford said the deal expands...
Bayer’s oral FXIa drug clears a late-stage hurdle – phase III stroke win
Bayer reported that its oral factor XIa inhibitor asundexian met the primary endpoint in a phase III trial, cutting the risk of recurrent ischemic stroke without increasing major bleeding. The...
Novo Nordisk’s semaglutide fails in Alzheimer’s: two phase III trials miss
Novo Nordisk disclosed top-line results showing oral semaglutide failed to slow clinical progression in two large phase III Alzheimer’s trials. The studies enrolled more than 3,800 patients with...
NervGen’s NVG‑291 shows durable gains in spinal cord injury — expanded CONNECT data
NervGen released expanded CONNECT SCI data showing NVG‑291 produced durable, broad functional improvements in people with chronic spinal cord injury, with benefits persisting at week 16 and in...
Biogen inks $50M pact with Versant‑backed Dayra for oral macrocycles in immunology
Biogen signed a collaboration with newly launched Dayra Therapeutics, paying $50 million up front to discover and optimize oral macrocyclic peptide candidates against immunological targets. Dayra,...
Tempus buys OneOme pharmacogenetics assets after lab shuts down
Tempus confirmed it has acquired the pharmacogenetics assets of OneOme, the Mayo Clinic spinout that abruptly ceased operations in November. The assets include OneOme’s RightMed PGx test and...
FDA staffing exodus: industry warns oversight is weakening
BioCentury reported an accelerating loss of FDA staff and experience, a trend that biopharma CEOs, investors and patient advocates warn is degrading regulatory oversight and making drug...
Plasmidsaurus launches ultrafast, $50 RNA‑seq service — cores on edge
Plasmidsaurus unveiled a shallow‑depth transcriptome sequencing service that promises 10 million deduplicated 3' reads per sample with a turnaround under three days and academic pricing at $50 per...
Cellarity debuts ToxPredictor: AI flags drug‑induced liver injury with high accuracy
Cellarity published a toxicogenomics‑based AI model, ToxPredictor, that leverages a DILImap library of transcriptional signatures from 300 compounds to predict drug‑induced liver injury (DILI)....
FDA opens probe into Takeda’s Adzynma after pediatric death and neutralizing antibodies
The FDA announced an investigation into Takeda’s Adzynma (approved 2023 for congenital thrombotic thrombocytopenic purpura) after reports that patients developed neutralizing antibodies and a...
Abbott doubles down on oncology diagnostics: Exact Sciences buyout
Abbott announced a definitive agreement to acquire Exact Sciences for $23 billion, a transaction the company says will immediately expand its diagnostics footprint into oncology screening, therapy...
Bayer’s oral FXIa inhibitor hits phase III stroke endpoint
Bayer reported top-line Phase 3 results showing its oral factor XIa inhibitor asundexian reduced recurrent ischemic stroke risk when added to standard antiplatelet therapy, meeting the trial’s...
Novo Nordisk’s semaglutide fails to slow Alzheimer’s in two large trials
Novo Nordisk disclosed negative Phase 3 results for oral semaglutide in Alzheimer’s disease: two large trials showed no effect on clinical progression versus placebo in patients with early...
Johnson & Johnson halts anti‑tau program after negative mid‑stage readout
Johnson & Johnson stopped a mid‑stage trial of its anti‑tau monoclonal antibody posdinemab after an interim analysis found the drug did not outperform placebo on clinical endpoints, the company...